Scynexis Stock Discussion

$Scynexis(SCYX.US)$ I would very much like to be informed of more progress in their dealing with the ibrexafungerp cross contamination issue. Couldn't find anything useful nonetheless.

$Scynexis(SCYX.US)$ 16 June……… good news coming! diamond hands

$Scynexis(SCYX.US)$ Drop more for a better price

$Scynexis(SCYX.US)$ holddddddd

$Scynexis(SCYX.US)$
$Nanoviricides(NNVC.US)$
$Tenet Healthcare(THC.US)$
I want to watch these the most, I think, and now to find stuff in a different sector..

$Scynexis(SCYX.US)$ SCYNEXIS (NASDAQ:SCYX) reported quarterly earnings of $0.01 per share which beat the analyst consensus estimate of $(0.20) by 105 percent. The company reported quarterly sales of $1.400 million which beat the analyst consensus estimate of $303.000 thousand by 362.05 percent. This is a 23.89 percent increase over sales of $1.130 million the same period last year.

$Scynexis(SCYX.US)$ -- SCY-247's IND-enabling activities continue to progress, with initiation
of Phase I anticipated in the second half of 2024
-- Clinical study reports for the FURI, CARES and NATURE trials in
refractory invasive fungal infections remain on track for delivery to GSK
in mid 2024, which would trigger a $10 million development milestone
payment to SCYNEXIS
-- SCYNEXIS ended Q1 2024 with cash, cash equivalents and investments of
$94.2 million and projects a cash ...

$Scynexis(SCYX.US)$
NEWS
SCYNEXIS to Present Preclinical Data on Second Generation Fungerp SCY-247 at the 34th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID)
SCYNEXIS, Inc. (SCYX) announces the presentation of preclinical efficacy data on SCY-247 at ECCMID 2024, focusing on addressing systemic fungal diseases and invasive fungal infections. SCY-247 shows promise in overcoming drug-resistant infections, particularly against Candida auris.